Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
作者信息
Van Gool Stefaan W, Makalowski Jennifer, Kampers Linde F C, Van de Vliet Peter, Sprenger Tobias, Schirrmacher Volker, Stücker Wilfried
机构信息
Immun-Onkologisches Zentrum Köln, Köln, Germany.
出版信息
Transl Cancer Res. 2023 Aug 31;12(8):2224-2228. doi: 10.21037/tcr-23-603. Epub 2023 Jul 28.
Abstract
摘要
相似文献
1
Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?多形性胶质母细胞瘤患者的树突状细胞疫苗接种：是否已达成新的里程碑？
Transl Cancer Res. 2023 Aug 31;12(8):2224-2228. doi: 10.21037/tcr-23-603. Epub 2023 Jul 28.
2
DCVax®-L--developed by Northwest Biotherapeutics.DCVax®-L——由西北生物治疗公司研发。
Hum Vaccin Immunother. 2014;10(11):3139-45. doi: 10.4161/hv.29276.
3
DCVax-Brain and DC vaccines in the treatment of GBM.DCVax-Brain与DC疫苗治疗胶质母细胞瘤
Expert Opin Investig Drugs. 2009 Apr;18(4):509-19. doi: 10.1517/13543780902841951.
4
Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model.基于多参数 MRI 的预测模型评估树突状细胞瘤苗治疗胶质母细胞瘤的疗效。
J Neurooncol. 2023 May;163(1):173-183. doi: 10.1007/s11060-023-04324-4. Epub 2023 May 2.
5
Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana?胶质母细胞瘤中自体肿瘤裂解物负载树突状细胞疫苗接种（DCVax-L）：突破还是海市蜃楼？
Neuro Oncol. 2023 Apr 6;25(4):631-634. doi: 10.1093/neuonc/noac281.
6
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.初现曙光：自体树突状细胞瘤疫苗治疗新诊断胶质母细胞瘤 III 期临床试验的生存结果。
J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6.
7
DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open.胶质母细胞瘤患者使用DCVax-L疫苗：是真正带来希望还是试验结果不佳？争论已经展开。
Cancers (Basel). 2023 Jun 20;15(12):3251. doi: 10.3390/cancers15123251.
8
Technology evaluation: DCVax, Northwest Biotherapeutics.技术评估：DCVax，西北生物治疗公司。
Curr Opin Mol Ther. 2002 Aug;4(4):403-7.
9
Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence?自体肿瘤裂解物负载树突状细胞瘤苗免疫治疗脑胶质瘤：证据去哪儿了？
Rev Neurol (Paris). 2023 Jun;179(5):502-505. doi: 10.1016/j.neurol.2023.03.014. Epub 2023 Apr 1.
10
Advances and challenges: dendritic cell vaccination strategies for glioblastoma.进展与挑战：胶质母细胞瘤的树突状细胞疫苗接种策略
Expert Rev Vaccines. 2017 Jan;16(1):27-36. doi: 10.1080/14760584.2016.1218762. Epub 2016 Aug 10.
引用本文的文献
1
Advancing vaccine-based immunotherapy in glioblastoma treatment.推进基于疫苗的免疫疗法用于胶质母细胞瘤治疗。
Neurooncol Adv. 2025 Jun 24;7(1):vdaf135. doi: 10.1093/noajnl/vdaf135. eCollection 2025 Jan-Dec.
2
Therapeutic Efficacy of CD34-Derived Allogeneic Dendritic Cells Engineered to Express CD93, CD40L, and CXCL13 in Humanized Mouse Models of Pancreatic Cancer.在胰腺癌人源化小鼠模型中，经工程改造表达CD93、CD40L和CXCL13的CD34来源的同种异体树突状细胞的治疗效果。
Vaccines (Basel). 2025 Jul 12;13(7):749. doi: 10.3390/vaccines13070749.
3
The Complexity of Malignant Glioma Treatment.恶性胶质瘤治疗的复杂性
Cancers (Basel). 2025 Mar 4;17(5):879. doi: 10.3390/cancers17050879.
4
Preclinical evaluation of DC-CIK cells as potentially effective immunotherapy model for the treatment of glioblastoma.树突状细胞-细胞因子诱导的杀伤细胞（DC-CIK）作为治疗胶质母细胞瘤潜在有效免疫治疗模型的临床前评估。
Sci Rep. 2025 Jan 3;15(1):734. doi: 10.1038/s41598-024-84284-5.
5
Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature.胶质母细胞瘤患者自体肿瘤裂解物负载树突状细胞疫苗接种：文献系统评价
Clin Transl Oncol. 2024 Dec 23. doi: 10.1007/s12094-024-03830-9.
6
Current Combinatorial Therapeutic Aspects: The Future Prospect for Glioblastoma Treatment.当前的联合治疗方面：胶质母细胞瘤治疗的未来前景
Curr Med Sci. 2024 Dec;44(6):1175-1184. doi: 10.1007/s11596-024-2950-7. Epub 2024 Dec 19.
7
Updates in Immunotherapy for Pancreatic Cancer.胰腺癌免疫治疗的进展
J Clin Med. 2024 Oct 26;13(21):6419. doi: 10.3390/jcm13216419.
8
The tumour microenvironment, treatment resistance and recurrence in glioblastoma.脑胶质瘤中的肿瘤微环境、治疗抵抗和复发。
J Transl Med. 2024 Jun 6;22(1):540. doi: 10.1186/s12967-024-05301-9.
9
Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives.胶质母细胞瘤治疗的免疫治疗策略：当前挑战与未来展望
Cancers (Basel). 2024 Mar 25;16(7):1276. doi: 10.3390/cancers16071276.
本文引用的文献
1
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience.针对异柠檬酸脱氢酶1（IDH1）野生型胶质母细胞瘤成人患者的个体化多模式免疫疗法：单机构经验
Cancers (Basel). 2023 Feb 13;15(4):1194. doi: 10.3390/cancers15041194.
2
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.自体肿瘤裂解物负载树突状细胞疫苗接种与新诊断和复发性胶质母细胞瘤患者生存延长的相关性：一项 3 期前瞻性外部对照队列试验。
JAMA Oncol. 2023 Jan 1;9(1):112-121. doi: 10.1001/jamaoncol.2022.5370.
3
Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis.树突状细胞疫苗接种对胶质母细胞瘤患者生存的延迟效应：系统评价和荟萃分析。
Curr Oncol. 2022 Feb 4;29(2):881-891. doi: 10.3390/curroncol29020075.
4
Clinical endpoints in oncology - a primer.肿瘤学中的临床终点——入门指南。
Am J Cancer Res. 2021 Apr 15;11(4):1121-1131. eCollection 2021.
5
Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?新诊断胶质母细胞瘤随机对照III期试验的真实世界有效性：试验结果适用于谁？
Neurooncol Adv. 2021 Feb 26;3(1):vdab008. doi: 10.1093/noajnl/vdab008. eCollection 2021 Jan-Dec.
6
Clinical trials using oncolytic viral therapy to treat adult glioblastoma: a progress report.使用溶瘤病毒治疗成人胶质母细胞瘤的临床试验：进展报告。
Neurosurg Focus. 2021 Feb;50(2):E3. doi: 10.3171/2020.11.FOCUS20860.
7
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged.针对胶质母细胞瘤的随机对照免疫治疗临床试验面临挑战。
Cancers (Basel). 2020 Dec 24;13(1):32. doi: 10.3390/cancers13010032.
8
Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: A meta-analysis of randomized controlled trials.树突状细胞瘤苗治疗胶质母细胞瘤患者的有效性和安全性的 Meta 分析：随机对照试验研究。
Int Immunopharmacol. 2020 Jun;83:106336. doi: 10.1016/j.intimp.2020.106336. Epub 2020 Mar 23.
9
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.肿瘤治疗电场（TTFields）与抗 PD-1 治疗联合使用时，可诱导免疫原性细胞死亡，从而增强抗肿瘤疗效。
Cancer Immunol Immunother. 2020 Jul;69(7):1191-1204. doi: 10.1007/s00262-020-02534-7. Epub 2020 Mar 6.
10
Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.免疫表型与接受基于替莫唑胺的标准治疗和免疫治疗的胶质母细胞瘤患者的生存相关。
Anticancer Res. 2019 Apr;39(4):2043-2051. doi: 10.21873/anticanres.13315.
Zotero 插件